novo nordisk alzheimer

Alzheimer's, Novo Nordisk

Analysis-Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.

· 8h

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's

· 3h

Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says

Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

1don MSN

Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Fierce Pharma

Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results